Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus.
OBJECTIVE
We have compared the efficacy of posaconazole and amphotericin B in an experimental murine model of paecilomycosis.


METHODS
Immunosuppressed mice were treated with posaconazole at 25, 50, 75 or 100 mg/kg/day orally, amphotericin B at 1.5 or 3 mg/kg/day intraperitoneally or liposomal amphotericin B at 5 mg/kg/day intravenously. Treatment began 1 day after infection and continued for 10 days post-infection. Two strains of Paecilomyces lilacinus were tested.


RESULTS
Posaconazole at 50 mg/kg/day was the only treatment able to significantly reduce fungal loads in the spleens, kidneys and livers of the mice infected by each of the two strains.


CONCLUSIONS
The results suggest that posaconazole may have a clinical role in the treatment of disseminated paecilomycosis.
Rodríguez
M Mar
MM
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain.
Pastor
F Javier
FJ
Serena
Carolina
C
Guarro
Josep
J
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D007668:Kidney / Q000382:microbiology; D008099:Liver / Q000382:microbiology; D008297:Male; D051379:Mice; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D010143:Paecilomyces / Q000187:drug effects*; D013154:Spleen / Q000382:microbiology; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C068538:liposomal amphotericin B; C101425:posaconazole; D000666:Amphotericin B